Bioxytran Expands Institutional Investor Base With an Additional $500,000 Equity Investment
Bioxytran Expands Institutional Investor Base With an Additional $500,000 Equity Investment
- Funding in place to meet next regulatory milestone
-資金到位，以滿足下一個監管里程碑
BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing anti-viral oral drugs to treat retroviruses like SARS-CoV-2 which cause COVID-19 and other viral diseases, announced that it has entered into a common stock purchase agreement with TRITON FUNDS LP for $500,000. The proceeds will help kickstart the dosage optimization study for mild to moderate COVID-19, which has already received the regulatory approval to proceed with dosing. TRITON FUNDS is the second institutional investor aligning its investment strategy with the lead institutional investor Walleye Capital, LLC which was founded in 2005 and now has $5 billion plus of assets under management.
波士頓，馬薩諸塞州，2023年6月12日(Global Newswire)--BIOXYTRAN，Inc.北京--一家臨床階段生物技術公司BIXT(“該公司”)宣佈，它已與Triton Funds LP簽訂了一項價值50萬美元的普通股購買協定。該公司開發抗病毒口服藥物來治療導致新冠肺炎和其他病毒性疾病的SARS-CoV-2等逆轉錄病毒。所得資金將幫助啟動輕中度新冠肺炎的劑量優化研究，該研究已經獲得監管部門的批准，可以繼續進行劑量研究。Triton Funds是第二家與主要機構投資者Walleye Capital LLC保持投資戰略一致的機構投資者，Walleye Capital LLC成立於2005年，目前管理著超過50億美元的資產。
The funding is sufficient to reach the next milestone of a submission of a Phase 3 regulatory trial in India for mild to moderate COVID-19. Bioxytran's Clinical Research Organization (CRO) has indicated that dosing in the 40-patient trial is expected to commence within the month now that the funding is in place.
這筆資金足以達到下一個里程碑，即在印度提交新冠肺炎輕中度監管試驗的第三階段。Bioxtran的臨床研究組織(CRO)已經表示，由於資金到位，預計在40名患者參與的試驗中劑量將在一個月內開始。
"As a cornerstone of our investment portfolio, TRITON FUNDS has been meticulously and strategically trying to build a robust position in Bioxytran over the past year", said Axel Olson, Equity Analyst and Entrepreneur in Residence at TRITON FUNDS. "Our investment not only serves to solidify our cost basis but, more importantly, empowers Bioxytran with the necessary capital infusion to propel them towards their impending milestone."
Triton Funds股票分析師兼常駐企業家阿克塞爾·奧爾森表示：“作為我們投資組合的基石，Triton Funds在過去一年裡一直在一絲不苟地、戰略性地努力在Bioxtran建立穩固的頭寸。”我們的投資不僅鞏固了我們的成本基礎，更重要的是，為Bioxtran提供了必要的資本注入，推動他們邁向即將到來的里程碑。“
He added, "Having observed the company's trajectory for well over a year, we've been profoundly inspired by the tenacity and resilience of the management team, who have navigated with aplomb amidst a challenging regulatory and financial terrain. We are firm believers in the transformational potential of Bioxytran's technological prowess, a promising beacon that could drastically alter the treatment landscape for viral diseases. This investment represents our steadfast confidence in Bioxytran's capacity to usher in a new era in medical science."
他補充說：“在觀察了公司一年多的發展軌跡後，我們被管理團隊的堅韌和韌性深深鼓舞，他們在充滿挑戰的監管和金融領域泰然處之。我們堅信Bioxtran的技術實力具有變革潛力，這是一個有望徹底改變病毒疾病治療格局的燈塔。這筆投資代表了我們對Bioxtran有能力開創醫學新紀元的堅定信心。”
About Bioxytran, Inc.
關於雙氧雜環丙烷公司
Bioxytran, Inc. is a clinical stage biotechnology company developing novel therapies targeting the treatment of significant unmet medical needs in virology, degenerative disease, and hypoxia. The leading drug candidate, Prolectin-M, is a new class of antiviral drugs called Galectin Antagonists designed to neutralize galectins implicated in inflammatory, fibrotic, and malignant diseases. Bioxytran's other development programs are for pulmonary fibrosis and stroke treatment. More information can be found at
Bioxtran，Inc.是一家臨床階段的生物技術公司，開發新的療法，旨在治療病毒學、退行性疾病和缺氧方面尚未得到滿足的重大醫療需求。領先的候選藥物Prolectin-M是一種名為Galectin拮抗劑的新型抗病毒藥物，旨在中和與炎症、纖維化和惡性疾病有關的Galectins。Bioxtran的其他開發專案是肺纖維化和中風治療。欲瞭解更多資訊，請訪問
About TRITON FUNDS
關於Triton基金
As the nation's premier student-managed fund, TRITON FUNDS empowers students with real-world experience in Venture Capital and Private Equity. Our millennial-driven, alternative investment strategies foster growth and transformation in promising industries. We champion a growth cycle that benefits students, investors, and the broader community. Discover more at .
作為美國首屈一指的學生管理基金，Triton Funds使學生能夠在風險投資和私募股權方面擁有現實世界的經驗。我們以千禧年為導向的另類投資戰略促進了前景看好的行業的增長和轉型。我們倡導一個有利於學生、投資者和更廣泛社區的增長週期。瞭解更多資訊，請訪問。
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
投資者關係
邁克爾·謝赫
509-991-0245
郵箱：mike.sheikh@bioxtraninc.com
Forward-Looking Statements
前瞻性陳述
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words "believe," "expect," "anticipate," "estimate," "intend," "plan," and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran's actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
本新聞稿包括聯盟法律規定的前瞻性陳述，包括本新聞稿中描述的與技術性能有關的陳述。這些前瞻性表述通常由“相信”、“預期”、“預期”、“估計”、“打算”、“計劃”以及類似的表述來識別，儘管並不是所有前瞻性表述都包含這些可識別的詞語。此類陳述會受到重大風險、假設和不確定性的影響。已知的可能導致Bioxtran的實際結果與這些前瞻性陳述預期的結果大不相同的重大因素在前瞻性陳述中描述，風險因素在公司截至2021年12月31日的財政年度的Form 10-K年度報告中描述，這些風險因素在提交給美國證券交易委員會的其他檔案中不時列出。除聯盟證券法要求的範圍外，Bioxtran沒有義務糾正或更新任何前瞻性陳述，無論是由於新資訊、未來事件或其他原因。
譯文內容由第三人軟體翻譯。